Related Experiment Video

Updated: Jun 10, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K

Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future

Samuele Compagno1,2, Chiara Casadio1,2, Linda Galvani1,2

  • 1Medical Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Journal of Clinical Medicine
|October 16, 2024
PubMed

Insights

Immune checkpoint inhibitors (ICI) are key for renal cell carcinoma (RCC). Research explores new targets like TIGIT, LAG-3, and TIM-3 to overcome resistance and improve immunotherapy effectiveness in RCC patients.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immune checkpoint inhibitors (ICI) are standard treatments for renal cell carcinoma (RCC).
  • Cancer cells can develop adaptive resistance to current ICI therapies.
  • Exploring novel immune checkpoint pathways is crucial for advancing RCC treatment.

Purpose of the Study:

  • To review current knowledge on novel immunotherapy strategies for RCC.
  • To analyze the mechanisms of action and clinical activity of emerging immunotherapeutic agents.
  • To summarize ongoing clinical studies investigating new treatments for RCC.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of mechanisms of action for novel immunotherapeutic targets.
  • Compilation of data on clinical studies investigating new RCC treatments.

Main Results:

  • Identified T cell immunoglobulin and ITIM domain (TIGIT), immunoglobulin-like transcript 4 (ILT4), lymphocyte-activation gene-3 (LAG-3), and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) as promising targets.
  • Highlighted the potential of vaccines and chimeric antigen receptor (CAR) T cells in RCC immunotherapy.
  • Summarized the current status and activity of ongoing clinical trials for these novel agents.

Conclusions:

  • Novel immunotherapeutic targets and strategies show promise in overcoming ICI resistance in RCC.
  • Further clinical investigation is warranted to establish the efficacy of these emerging treatments.
  • Combination therapies targeting multiple immune checkpoints may offer enhanced outcomes for RCC patients.
Keywords:
ICIILT4LAG-3RCCTIGITTIM-3immune checkpoint inhibitorsimmunotherapyrenal cell carcinomavaccine

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

248

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K